Latest news with #AgingCell
Mint
2 days ago
- Health
- Mint
Do longevity drugs work?
As elixirs of life go, long-term fasting is a surprising candidate. Yet it seems to work. Experiments on species from nematode worms to rhesus monkeys show that near-starvation prolongs lifespan. And, though no long-term experiment has been conducted to prove the same is true in Homo sapiens, short-term ones suggest similar physiological changes happen. Mysteriously, however, most people are loth to trade three square meals a day in the here and now for the promise of a longer retirement, so the search has been on for chemical alternatives to fasting. Two molecules in particular have attracted attention: rapamycin, an immunosuppressant used to stop the rejection of transplanted kidneys, and metformin, an anti-diabetes drug. June 19th saw the publication of a paper summarising the evidence of their effectiveness in animals, compared with fasting. Both rapamycin and metformin have drawn the attention of the 'live for ever" brigade because they inhibit what is known as the mTOR pathway (indeed, mTOR stands for 'mechanistic target of rapamycin"). Overactivation of this in old age is associated with hallmarks of ageing such as inflammation. Conversely, fasting suppresses mTOR activity. That promotes autophagy, a phenomenon in which cells clear out their accumulated crud, which is reckoned lifespan-enhancing. Moreover, both substances also have the advantages of having undergone safety trials as part of approval for their on-label uses, and of being off-patent, and therefore cheap. Being off-patent, however, cuts both ways. It means commercial sponsors for human clinical trials are hard to find, since they cannot monopolise sales. As a result the Targeting Ageing with Metformin (TAME) trial, a proposal sponsored by the American Federation for Aging Research, a charity, and approved by the Food and Drug Administration in 2015, remains in abeyance for lack of funds. Rapamycin, by contrast, has been tested in what is known as the PEARL (Participatory Evaluation of Ageing with Rapamycin for Longevity) trial, which began in July 2020. But this found no strong evidence that it worked. Animal tests have proved more definitive. The new paper, published in Aging Cell by Edward Ivimey-Cook of Glasgow University and his colleagues, gathers all the vertebrate-trial evidence that the authors could find. This amounts to 167 studies on eight species, ranging from fish to monkeys. The answers seem clear-cut. To no one's surprise, calorie restriction works. So, to a pretty-much equal extent, does rapamycin. But metformin does not. That is a blow to those, their number unknown but probably amounting to thousands, who have twisted their doctors' arms to get an off-label prescription of it for life extension. But it is a boost to those who have opted for rapamycin. These include Vinod Khosla, one of Silicon Valley's best-known venture capitalists, and, until recently, Bryan Johnson, another Californian techie, who has made a second career out of his quest for immortality. Mr Johnson, however, dropped rapamycin in 2024 because of its side-effects (abnormal lipid and glucose levels, elevated heart rate and increased risk of skin infection). All of which is interesting. But for mere mortals who want a long and healthy life without the risk of rapamycin's side-effects the advice remains the same: eat wisely, drink moderately, exercise regularly, sleep well. And stub that cigarette out. Curious about the world? To enjoy our mind-expanding science coverage, sign up to Simply Science, our weekly subscriber-only newsletter. © 2025, The Economist Newspaper Limited. All rights reserved. From The Economist, published under licence. The original content can be found on
The Hindu
10-06-2025
- Health
- The Hindu
Scientists uncover molecular clue to slow down reproductive aging
Researchers at the National Institute of Animal Biotechnology (NIAB) have made a significant discovery that could pave the way for new strategies to extend female fertility. Led by Prasad Rao from NIAB's Laboratory of Molecular Reproduction and Aging, the team has uncovered a molecular clue that appears to slow down reproductive aging. The scientific team, using both live mouse models and cultured goat ovaries, found that reducing the activity of a cellular protein called 'Cathepsin B' (Cat B) helps preserve the ovarian reserve. This ovarian reserve is the finite pool of egg cells (oocytes) that female mammals are born with. Unlike sperm, these crucial egg cells cannot be regenerated. The findings are important since, unlike sperm, oocytes cannot be regenerated. 'Over time, the quantity and quality of these eggs naturally decline due to factors like oxidative stress, inflammation and general cellular wear. This process accelerates with age. 'Cat B,' a protein-degrading enzyme, seems to be a key driver of this decline. By lowering its levels, we may be able to delay egg loss, effectively extending fertility naturally,' said The scientist team, which includes Aradhana Mohanty, Anjali Kumari, Lava Kumar S., Ajith Kumar, Pravin Birajdar, Rohit Beniwal, Mohd Athar and Kiran Kumar P., pointed out that the implications go far beyond the laboratory. It is because across India's rural heartlands and urban hospitals, fertility is quietly becoming a shared crisis. As both livestock and women age, their ability to reproduce declines, with significant biological and economic consequences, said researchers. In humans, fertility begins to decline in the early 30s, with a sharper drop in the 40s, reducing chances of conception and increasing the risk of miscarriage or chromosomal disorders. While assisted reproductive technologies like IVF provide options, they are often costly, invasive and less effective in older women. A safe, biological method to slow ovarian ageing could revolutionise fertility preservation for millions. For farmers, a simple intervention to extend reproductive lifespan of livestock could improve herd productivity, reduce stray cattle populations, and support the incomes of smallholder farmers who form the backbone of Indian agriculture. This is a rare moment where science serves both the farm and the family. From barns to birthing rooms, this discovery bridges animal science and human medicine, promising a future where age is no longer a barrier to reproduction, said researchers. For a country navigating the twin challenges of rural sustainability and reproductive health, the implications are profound and hopeful, said NIAB director G. Taru Sharma. The research results were published in the latest issue of 'Aging Cell'.
